DYNAGLIPT LM 5/500MG (Metformin (500mg) + Linagliptin (5mg))

Dynaglipt LM 500mg/5mg Tablet is a medicinal formulation combining two active ingredients aimed at managing elevated blood glucose levels in adults diagnosed with type 2 diabetes mellitus. The medication functions by enhancing the efficacy of insulin and diminishing glucose synthesis in the liver. It can be utilized as a standalone treatment or in conjunction with other anti-diabetic agents. Optimal results are typically achieved through a synergistic approach that includes adherence to a nutritious diet and regular physical activity. The prescribed dosage will vary based on individual health status, current blood sugar readings, and concurrent medications. It is advisable to take the tablet alongside meals to help reduce stomach discomfort. Adherence to the prescribed regimen is crucial; do not alter your dosage or discontinue use without consulting a healthcare provider first. Maintaining a structured eating plan and exercise routine is vital for effective diabetes management. Users should be aware of potential side effects such as headaches, nausea, feelings of dizziness, and skin rashes. Some patients may experience hypoglycemia, particularly if this medication is taken with other diabetes medications like insulin or sulfonylureas. Should any side effects persist or escalate, it’s important to seek medical advice promptly. Prior to commencing treatment with Dynaglipt LM 500mg/5mg Tablet, inform your healthcare provider of any existing kidney, liver, or heart conditions, as well as any history of pancreatic disorders. Pregnant or breastfeeding individuals should consult their healthcare provider for guidance, and it is important to communicate any other medications being taken to avoid potential interactions. Alcohol consumption is discouraged, as it may lead to lower blood sugar levels. Ongoing monitoring of kidney function and blood glucose levels will be performed by your healthcare provider during the course of treatment. Note that this medication is not indicated for the treatment of type 1 diabetes.